Analyst: Biotech to Have ‘Eventful Year’ with Data Readouts in Three Indications

Sourced from:

Also in the report, Arce temporarily outlined DURECT’s Q4/18 financials, suggesting revenue during the quarter was $3.6 million. At 2018, the company had $34.5 million in cash and cash equivalents, along with $20.5 million of money from a term loan.

Part A registration of average AH patients for your 90 mg dose continues. Both components could advance to the final 150 mg dose if the dose escalation committee decides the safety and pharmacokinetic profiles are adequate.

Psoriasis is your second sign for which DUR-928 data will be forthcoming. DURECT has scheduled enrollment for the Stage 2a proof-of-concept trial of topical DUR-928 for mild to moderate plaque psoriasis to begin at the end of the month. This 20-patient study will include four months of therapy, then a follow-up interval of exactly the identical duration.
One of those signs is alcoholic hepatitis (AH), which will be “emerging as a top priority sign for DUR-928,” mentioned Arce. Results later this year may come from a Stage 2a open label, multicenter dose escalation research now in progress.

None of those study analysts or the researcher’s household has a financial interest in the securities of DURECT Corporation (including, without limitation, any option, right, justify, future, long or short position).

At February 28, 2019 neither the Company nor its affiliates beneficially own 1% or more of any class of common equity securities of DURECT Corporation.

Members or her of her household own securities of these businesses mentioned in the article: Not one. Members or her of her family are paid by these companies discussed in this article: Not one.
Two ) The following firms discussed in this post are equipping sponsors of Streetwise Reports: DURECT Corp.. Click on here for significant disclosures about sponsor fees.
3) Opinions and opinions expressed are those of their specific experts rather than of Streetwise Reviews or its officers. The information supplied above is for informational purposes only and is not a recommendation to purchase or sell any security.
4) The content does not constitute investment advice. Every reader is invited to talk to her or his respective financial professional and any action a reader takes as a result of information presented here is their own duty. By opening this site, every reader agrees and accepts to Streetwise Reports’ terms of use and complete legal disclaimer. This article isn’t a solicitation for investment. Streetwise Reports does not leave general or specific investment advice and the advice on Streetwise Reports should not be considered a recommendation to buy or sell any security. Streetwise Reports does not endorse or recommend the business, goods, services or securities of any business mentioned on Streetwise Reports.
5) From time to time, Streetwise Reports LLC and its directors, officials, employees or associates of the families, as well as persons interviewed for interviews and articles on the site, might have a long or short position in securities mentioned. Employees, officers, employees or members of the immediate families are prohibited from making purchases and/or sales of these securities in the open market or otherwise from the time of their interview or the decision to compose an article until three business days after the publication of the interview or article. The foregoing prohibition doesn’t apply to articles that in substance only restate previously published firm releases.

Disclosures out of H.C. Wainwright & Co., DURECT Corporation, Earnings Update, March 8, 2019

From The Life Science Report
The research analyst primarily responsible for preparation of this report doesn’t receive compensation that’s based upon any specific investment banking services or trade but is paid based on factors such as total revenue and profitability of the Business, a significant portion of which comes from investment banking solutions.
The most recent news related to the study is from March 7, even when DURECT declared it had progressed the study to Part B, which is for severe AH patients in the 90 mg dose cohort. “The company decided to move forward in light of the “positive benefits in both moderate and severe AH patients who were awarded the 30 mg doses along with the rapid pace of enrollment in Section B, also ” the analyst wrote.
Neither the researcher nor the Firm has some material conflict of interest in of which the researcher knows or has reason to be aware in the time of publication of the study report.

I, Ed Arce and Thomas Yip, cautioned that 1) all of the viewpoints expressed in this report accurately reflect my personal views concerning any and all subject securities or issuers discussed; and 2) no part of my compensation was, is, or would be directly or indirectly linked to the particular recommendation or views expressed in this research report; and 3) neither myself nor any members of my family is an officer, director or advisory board member of these companies.

Source: Streetwise Reviews   03/12/2019
This California company anticipates results from clinical trials in liver disease and psoriasis at 2019.
Read what other pros are saying :